AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

Initial Statement of Beneficial Ownership

Insider	Title	Transaction Type	Shares Traded	% of Shares Traded	% Chg. in Shares	End of Filing Shares	Price	Transaction Value	Filing Date	Transaction Date
Susan E. Quaggin	Independent Director Show All	Other Derivative Acquisition (Other Derivative Acquisition)	67.0	—	11.8%	634.0	231.5 - 231.5	—	02 Oct 2025	30 Sep 2025 - 30 Sep 2025
Robert J. Alpern	Independent Director Show All	Other Derivative Acquisition (Other Derivative Acquisition)	33.0	—	0.3%	10.2K	231.5 - 231.5	—	02 Oct 2025	30 Sep 2025 - 30 Sep 2025
Edward Joseph Rapp	Independent Director Show All	Other Derivative Acquisition (Other Derivative Acquisition)	145.0	—	0.5%	28.2K	231.5 - 231.5	—	02 Oct 2025	30 Sep 2025 - 30 Sep 2025
Azita Saleki-Gerhardt	Executive VP & COO Show All	Derivative Exercise and Sale (Derivative Exercise and Sale)	-42.4K	-0.002398%	—	183.8K	54.9 - 198.4	-6.1M	14 Aug 2025	12 Aug 2025 - 12 Aug 2025
Nicholas J. Donoghoe	Executive VP and Chief Business & Strategy Officer Show All	Open Market Disposition (Open Market Disposition)	-13.3K	-0.000752%	-18.6%	58.2K	198.3 - 198.6	-2.6M	07 Aug 2025	05 Aug 2025 - 05 Aug 2025
Demetris D. Crum
Demetris D. Crum
Demetris D. Crum
	—
Robert J. Alpern
Susan E. Quaggin
Edward Joseph Rapp
Thomas J. Falk
Frederick H. Waddell
Robert J. Alpern
Roxanne S. Austin
William H. L. Burnside
Brett J. Hart
Thomas Craig Freyman
Thomas J. Falk
Thomas J. Falk
Glenn F. Tilton
Rebecca B. Roberts
Susan E. Quaggin
Melody Boone Meyer
Jennifer L. Davis
Edward Joseph Rapp
Richard A. Gonzalez
Jeffrey Ryan Stewart
Jeffrey Ryan Stewart